Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-human, Randomised, Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZP8396 Administered to Healthy Subjects

Next Previous
X
Search
Trial Profile

A First-in-human, Randomised, Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZP8396 Administered to Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 02 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Petrelintide (Primary) ; Petrelintide (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Adverse reactions; First in man
  • Sponsors Zealand Pharma

    • Most Recent Events

    • 26 Jun 2023 Results (n=56) assessing safety, pharmacokinetics, and pharmacodynamics of a single subcutaneous injection of ZP8396 in healthy lean and overweight male subjects presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
    • 24 Jun 2023 According to a Zealand Pharma media release, results from this study presented at the 2023 American Diabetes Associations 83rd Scientific Sessions
    • 24 Jun 2023 Results published in the Zealand Pharma Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top